3/31
08:11 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
3/27
06:19 pm
ibrx
"This Is Existential": Billionaire Cancer Researcher Says Covid & Vaccine Likely Causing Surge In Aggressive Cancers [zero hedge]
Medium
Report
"This Is Existential": Billionaire Cancer Researcher Says Covid & Vaccine Likely Causing Surge In Aggressive Cancers [zero hedge]
3/26
06:12 am
ibrx
ImmunityBio to Host Investor Day [Yahoo! Finance]
Low
Report
ImmunityBio to Host Investor Day [Yahoo! Finance]
3/26
06:00 am
ibrx
ImmunityBio to Host Investor Day
Low
Report
ImmunityBio to Host Investor Day
3/25
08:13 pm
ibrx
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? [Yahoo! Finance]
Low
Report
Is ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket? [Yahoo! Finance]
3/13
01:58 pm
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/13
10:10 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
3/13
09:00 am
ibrx
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
Low
Report
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
3/7
01:48 am
ibrx
https://seekingalpha.com/article/4765586-immunitybio-stock-q4-bcg-shortage-and-tariff-risks-could-stifle-anktivas-commercial-momentum [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4765586-immunitybio-stock-q4-bcg-shortage-and-tariff-risks-could-stifle-anktivas-commercial-momentum [Seeking Alpha]
3/6
07:26 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
3/3
07:37 am
ibrx
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 [Yahoo! Finance]
High
Report
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 [Yahoo! Finance]
3/3
07:30 am
ibrx
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
High
Report
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
2/28
08:36 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Medium
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
2/27
09:00 pm
ibrx
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Medium
Report
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2/27
07:38 pm
ibrx
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer [Yaho
Medium
Report
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer [Yaho
2/27
07:10 pm
ibrx
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
High
Report
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
2/19
11:17 pm
ibrx
Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? [Yahoo! Finance]
Medium
Report
Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday? [Yahoo! Finance]
2/19
09:29 am
ibrx
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage [Yahoo! Finance]
High
Report
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage [Yahoo! Finance]
2/19
09:00 am
ibrx
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
High
Report
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
2/14
08:07 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Medium
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
2/13
03:26 pm
ibrx
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! Finance
Low
Report
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! Finance
2/13
03:05 pm
ibrx
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Low
Report
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
1/29
09:29 am
ibrx
ImmunityBio announces collaboration with Beigene [Seeking Alpha]
Medium
Report
ImmunityBio announces collaboration with Beigene [Seeking Alpha]
1/29
08:30 am
ibrx
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Low
Report
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
1/27
10:19 am
ibrx
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.
Low
Report
ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.